Table 1.
Patient demographics and disease characteristics
| Characteristic | Lapatinib + vinorelbine (N=44)* |
|---|---|
| Age, years | |
| Median (range) | 56.0 (29–82) |
| Race, n (%) | |
| Caucasian/White | 32 (73) |
| African American/African heritage | 12 (27) |
| ECOG status at baseline, n (%) | |
| 0 | 25 (57) |
| 1 | 19 (43) |
| HER2 status, n (%) | |
| FISH+ (with or without IHC+) | 27 (61) |
| IHC 3+ (only) | 29 (66) |
| ER/PgR status, n (%) | |
| ER+ and/or PgR+ | 23 (52) |
| ER- and PgR- | 21 (48) |
| Stage at initial diagnosis, n (%) | |
| 0 | 1 (2) |
| I | 3 (7) |
| II | 15 (34) |
| III | 14 (32) |
| IV | 11 (25) |
| Number of prior metastatic chemotherapeutic regimen (s), n (%) | |
| 0 | 23 (52) |
| 1 | 21 (48) |
| Median time since first diagnosis, months (range) | 28.8 (1–126) |
| Prior anti-cancer therapy, n (%) | 43 (98) |
| Chemotherapy | 35 (80) |
| Immunotherapy | 1 (2) |
| Hormonal therapy | 18 (41) |
| Biologic therapy | 35 (80) |
| Surgery | 43 (98) |
| Radiotherapy | 23 (52) |
*All patients were female. ECOG, Eastern Cooperative Oncology Group; ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER2, Human epidermal growth factor receptor 2; IHC, immunochemistry; PgR, progesterone receptor.